Alembic Pharmaceuticals Ltd. - Quarterly/Annual Result Disclosures and Notes dated 31 Mar 2021
Auditor and Management Disclosures and Notes for the annual results dated 31 Mar 2021
1. The above standalone results, have been reviewed by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors of the Company.
2. Additional information to investors are provided hereunder: a) Research and Development Expenses: For Table, kindly refer Corporate Announcements on www.bseindia.com.
3. The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment.
4. Asset cover available : 10.51 times.
5. The previous and the next due date(s) for payment of interest & principal on unsecured non-convertible debentures is provided hereunder. No principal amount is due till 31st March, 2021. The interest for the previous due date(s) have been paid on the respective due dates. For Table, kindly refer Corporate Announcements on www.bseindia.com.
6. The Company is rated by leading credit agency CRISIL. The rating "AA+/Stable" and "CRISIL Al+" has been assigned for long term and short term facility respectively.
7. Debenture Redemption Reserve Rs. 125 Crores.
8. Ratios: a) Debt to Equity: Debt/ Net Worth Debt : Total Debt ( Short term + Long term) Net worth : Share Capital + Reserves & Surplus
b) Debt Service Coverage Ratio: EBIT / (Interest on tenm & working capital debt + schedule principal repayments of Long term debt) (EBIT : Profit before Taxes + Interest)
c) Interest Service Coverage Ratio : EBIT / Interest
d) Asset Coverage ratio: as per formula prescribed under SEBI Circular No. SEBI/HO/MIRSD/CRADT/CIR/P/2020/230 Dated 12-11-2020.
9. The Board has recommended dividend on Equity Shares at Rs 14 per share i.e. 700% for the year ended on 31.03.2021 as against the Interim Dividend of Rs. 7/- (350%) per equity share and an additional Special Dividend of Rs. 3/· (150%) per equity share aggregating to total Interim Dividend of Rs. 10/- (500%) per equity share for the financial year 2019-20.
10. The figures of 3 months ended 31st March 2021 and corresponding 3 months ended on 31st March 2020 are the balancing figures between the audited figures in respect of full financial year and year to date figures up to the third quarter of the respective financial years.
11. The previous quarter's/ year's figures have been regrouped/ rearranged wherever necessary to make it comparable with the current quarter/ period.